Literature DB >> 3514616

Purification and characterization of an acid metalloproteinase from human articular cartilage.

W Azzo, J F Woessner.   

Abstract

A metalloprotease that digests cartilage proteoglycan optimally at pH 5.3 has been purified (4400-fold) to homogeneity from 20-g samples of human articular cartilage containing about 100 micrograms of enzyme. This enzyme was cleanly separated from a related neutral metalloprotease with an optimum pH of 7.2. The acid metalloprotease displays 40% of its maximum activity at pH 7.2 and so has significant activity at physiological pH. The protease is calcium-dependent and indirect evidence suggests that it may contain zinc at its active center. It occurs largely in a latent form that can be activated by aminophenylmercuric acetate. The apparent Mr of the latent form is 55,000 and of the active form, 35,000. The isoelectric point is at pH 4.9. The protease activity is inhibited by chelators, Z-phenylalanine, ovostatin, and tissue inhibitor of metalloproteinase from human articular cartilage. It differs from metalloproteinases such as enkephalinase and kidney brush-border protease in its failure to be strongly inhibited by phosphoramidon and Zincov. It cleaves the proteoglycan monomer of bovine nasal cartilage to fragments of approximately 140,000 Da. It cleaves the B chain of insulin at Ala14-Leu15 and Tyr16-Leu17. A survey of 26 cartilage extracts indicates this enzyme is elevated to about 3 times the normal level in human osteoarthritic cartilage and that the tissue inhibitor of metalloproteinase is only slightly diminished. Preliminary evidence points to the presence of a similar acid metalloprotease activity in human polymorphonuclear leukocytes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514616

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  MMPs and TIMPs--an historical perspective.

Authors:  J Frederick Woessner
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

2.  Purification and characterization of acidolysin, an acidic metalloprotease produced by Clostridium acetobutylicum ATCC 824.

Authors:  C Croux; V Paquet; G Goma; P Soucaille
Journal:  Appl Environ Microbiol       Date:  1990-12       Impact factor: 4.792

3.  Link protein as a monitor in situ of endogenous proteolysis in adult human articular cartilage.

Authors:  Q Nguyen; J Liu; P J Roughley; J S Mort
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

4.  Myocardial matrix metalloproteinase(s): localization and activation.

Authors:  S C Tyagi; A Ratajska; K T Weber
Journal:  Mol Cell Biochem       Date:  1993-09-08       Impact factor: 3.396

5.  Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells.

Authors:  S M Wilhelm; I E Collier; A Kronberger; A Z Eisen; B L Marmer; G A Grant; E A Bauer; G I Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

6.  Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3.

Authors:  Z Gunja-Smith; H Nagase; J F Woessner
Journal:  Biochem J       Date:  1989-02-15       Impact factor: 3.857

7.  Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage.

Authors:  D D Dean; J Martel-Pelletier; J P Pelletier; D S Howell; J F Woessner
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  Role of the conserved histidine and aspartic acid residues in activity and stabilization of human gelatinase B: an example of matrix metalloproteinases.

Authors:  T Pourmotabbed; J A Aelion; D Tyrrell; K A Hasty; C H Bu; C L Mainardi
Journal:  J Protein Chem       Date:  1995-10

9.  Preferential mRNA expression of prostromelysin relative to procollagenase and in situ localization in human articular cartilage.

Authors:  Q Nguyen; J S Mort; P J Roughley
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.